Home › Research › Drug development
mRNA vaccine platform demonstrates potent immunotherapeutic targeting of amyloid-β and tau pathologies in Alzheimer's disease
Wu H, Hou Y, Feng X, Xia X, Yu X, Kong W.. Research Square, 2025-09-16
Topic: Disease mechanisms in lab and animal studies
Current Alzheimer’s disease (AD) immunotherapeutics face efficacy and safety limitations with antibody-based approaches. While active immunization targeting Aβ and Tau pathologies represents a promising therapeutic avenue, existing peptide/protein vaccines fail to sustain adequate antibody titers or durable immune responses. mRNA vaccines offer a promising alternative, combining sustained immunogenicity, flexible antigen design, and favorable safety profiles. We developed an AD mRNA vaccine platform generating Aβ- and Tau-targeting candidates. These engineered vaccines induced robust, persistent antigen-specific antibodies in AD models without harmful T-cell responses or cerebrovascular complications. They mediated broad clearance of pathogenic aggregates across brain regions, resolved chronic neuroinflammation, and halted neurodegeneration-driven cognitive decline. Mechanistically, vaccine-induced antibodies crossed the blood-brain barrier, directly neutralized pathological proteins, enhanced microglial phagocytic activity, and modulated neuroinflammatory pathways, collectively restoring neuronal homeostasis. This mRNA platform overcomes key constraints of current clinical candidates by achieving potent pathological clearance while circumventing treatment-limiting toxicities, positioning mRNA-based active immunization as a transformative therapeutic strategy with near-term translational potential for AD.
Key findings
- We developed an AD mRNA vaccine platform generating Aβ- and Tau-targeting candidates.
- These engineered vaccines induced robust, persistent antigen-specific antibodies in AD models without harmful T-cell responses or cerebrovascular complications.
- They mediated broad clearance of pathogenic aggregates across brain regions, resolved chronic neuroinflammation, and halted neurodegeneration-driven cognitive decline.
- Mechanistically, vaccine-induced antibodies crossed the blood-brain barrier, directly neutralized pathological proteins, enhanced microglial phagocytic activity, and modulated neuroinflammatory pathways, collectively restoring neuronal homeostasis.
- This mRNA platform overcomes key constraints of current clinical candidates by achieving potent pathological clearance while circumventing treatment-limiting toxicities, positioning mRNA-based active immunization as a transformative therapeutic strategy with near-term translational potential for AD.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 16/100
Preprint — not yet peer-reviewed. It scored 19 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multi-centre collaboration, so those were left out: it earned 12 of the 62 points we could judge it on, which is 19 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 2 / 10 | Tier 4 — not a peer-reviewed journal (Research Square) |
| Journal's citation record | 0 / 4 | Not a journal article, so the journal's record does not count |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 4 / 10 | Preprint — not yet peer-reviewed. Hosted on a preprint server. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 12 / 62 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 12 of the 62 points we could judge it on is 19 out of 100. |
| Total | 19 / 100 | Capped to 16 because this is not a peer-reviewed article. |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
APA 7th
Wu, H., Hou, Y., Feng, X., Xia, X., Yu, X., & Kong, W. (2025). mRNA vaccine platform demonstrates potent immunotherapeutic targeting of amyloid-β and tau pathologies in Alzheimer's disease. Research Square. https://doi.org/10.21203/rs.3.rs-7514957/v1
Vancouver
Wu H, Hou Y, Feng X, Xia X, Yu X, Kong W. mRNA vaccine platform demonstrates potent immunotherapeutic targeting of amyloid-β and tau pathologies in Alzheimer's disease. Research Square. 2025. doi:10.21203/rs.3.rs-7514957/v1.
BibTeX
@article{wu2025-293b5940,
author = {Wu, H. and Hou, Y. and Feng, X. and Xia, X. and Yu, X. and Kong, W.},
title = {{mRNA vaccine platform demonstrates potent immunotherapeutic targeting of amyloid-β and tau pathologies in Alzheimer's disease}},
journal = {Research Square},
year = {2025},
doi = {10.21203/rs.3.rs-7514957/v1},
url = {https://doi.org/10.21203/rs.3.rs-7514957/v1}
}